Saturday - July 11, 2026
GSK's Licensor Hansoh Pharma Announces Positive Phase III Results for Ris-Rez in China Patient Population
July 11, 2026
LONDON, England, July 11 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 10, 2026:

* * *

GSK's licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population

* ARTEMIS-008, a phase III study conducted for China, met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer

* First positive phase III overall survival . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products